Sign in
No access yet? Request a demo and we'll be in touch.
It starts with your dictionary, not our model.
We define the data model with you first — the event types, their fields, which source wins, and how repeats resolve. These four carry the patient's whole course.
molecular alterations & expression
therapy starts, stops & switches
RECIST response per scan
performance status over time
Extraction reads one document at a time.
The patient's initial consult note. Click any highlighted phrase — extraction lifts a structured value, with its verbatim evidence and a character-level citation.
MERIDIAN ONCOLOGY ASSOCIATES · INITIAL CONSULT
CC: New diagnosis, stage IV lung adenocarcinoma.
Molecular: NGS panel (tissue, resulted 01/09/2025) identifies EGFR exon 19 deletion. No T790M, ALK, ROS1, or KRAS. PD-L1 IHC (22C3) TPS 15%.
ECOG: Performance status 1 (ambulatory).
Plan: Given the actionable EGFR deletion, initiate first-line Zenclavir 80 mg PO daily. Restaging CT in 12 weeks.
Four event-bearing extractions from this one note.
Resolution is where judgment lives.
Extraction is high-recall on purpose, so one fact shows up many times — restated and copied forward across every later note. A naive merge would take the latest mention. Resolution doesn't.
The source hierarchy anchors the event to the actual assay — the January molecular report — not the December note that quotes it. The rest are kept as citations, so your cohort never counts one biomarker four times, or dates it wrong.
What lands in your warehouse.
Four joined tables — Events, Extractions, Citations, Evaluations. Read down this one patient and the whole arc is there. Click any event to trace it to the note.
EGFR exon 19 deletion — Positive
Tissue NGS. The driver that sets first-line therapy.
Zenclavir — Started · 80 mg PO daily
Partial Response (RECIST 1.1)
Progressive Disease
The course turns here.
MET amplification — Positive (CN 8)
Plasma liquid biopsy. The resistance mechanism.
Zenclavir — Discontinued
Trevoxamab — Started
Second-line therapy after resistance.
Partial Response (RECIST 1.1)
Response to the switch.
| event | value | date |
|---|---|---|
| biomarker | EGFR exon 19 del | 2025-01-10 |
| treatment | Zenclavir · Started | 2025-01-10 |
| biomarker | MET amp (CN 8) | 2025-09-02 |
| treatment | Zenclavir · Discontinued | 2025-09-02 |